The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Platelet Function During Antihypertensive Treatment with Quinapril, a Novel Angiotensin Converting Enzyme Inhibitor
The effect of various antihypertensive medications on platelet function is of increasing interest . Conflicting effects of captopril on platelet function are reported and the impact of angiotensin converting enzyme ( ACE ) inhibitors not containing a sulfhydryl group such as enalapril , lisinopril , and quinapril on platelet function remains unstudied . Therefore , the aim of the present study was to examine the effect of antihypertensive treatment with quinapril , a novel ACE inhibitor not containing a sulfhydryl group , on platelet function . Ten white men ( age range of 32–61 years ) with untreated mild-to-moderate essential hypertension ( supine diastolic blood pressure > 95 mm Hg ) were treated with 4 weeks each of placebo and quinapril in a double-blind , r and omized , crossover design . Quinapril ( 20 mg twice a day ) significantly lowered systolic ( p < 0.01 ) and diastolic blood pressure ( p < 0.01 ) without any significant effect on heart rate or plasma catecholamines . No significant change was noted for in vitro platelet aggregation induced by epinephrine , ADP , or collagen . Plasma concentrations of the platelet release factors β-thromboglobulin and platelet factor 4 did not change , nor did the platelet content of norepinephrine , platelet weight ( mg/10 ml of blood ) , circulating platelet count , or platelet size . Thus , as assessed by a broad spectrum of platelet parameters , we found that antihypertensive treatment with quinapril has no significant effect on platelet function in patients with mild-to-moderate essential hypertension . These “ platelet-neutral ” properties of quinapril suggest that quinaparil , both from a thromboembolic and a hemostatic point of view , may be a rather safe agent for treatment of hypertension
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .